Vatiquinone

DB11917InvestigationalSmall molecule

Vatiquinone has been investigated for the treatment and prevention of Retinopathy, Rett Syndrome, Genetic Disease, Noise-induced Hearing Loss, and Methylmalonic Aciduria and Homocystinuria,Cblc Type.

Mechanism: Pharmacologically active on NAD(P)H dehydrogenase [quinone] 1
Curator reviewed
Formula / weight: C₂₉H₄₄O₃ · 440.668 g/mol (avg)
Code names: EPI-743 · PTC-743

Resolves to

Compound

UNII6O85FK9I0XCAS1213269-98-7ChEMBLCHEMBL1812161PubChem46184405

Structure

InChIKeyLNOVHERIIMJMDG-XZXLULOTSA-NSMILESCC(C)=CCC\C(C)=C\CC\C(C)=C\CC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O

Targets

P15559NQO1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

18Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Vatiquinone, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account